Skip to main content

International Health to Offer Provista's Breast Cancer Test in UK, Ireland

NEW YORK (GenomeWeb News) – Provista Life Sciences said today that International Health Technology will offer its early-stage breast cancer detection test in the United Kingdom and in Ireland.
 
Under the license agreement, IHT will offer the blood-based Biomarker Translation Test in its BreastHealth UK clinic this summer. The company said it plans to expand the availability of the test to other European Union countries sometime later, but did not provide further details on its timeline.
 
The company’s BT Test identifies multiple cancer-related proteins in blood samples and combines that information with the patient’s medical profile.
 
Phoenix, Ariz.-based Provista also said the test showed an accuracy rate above 80 percent for all women.
 
Financial terms of the agreement were not released.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.